Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexmarilimab Plus Pembrolizumab in Advanced NSCLC
NCT05171062Phase 1Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexmarilimab in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by UT Health San Antonio. Primary endpoints: Safety and tolerability and Programmed Death Cell Ligand 1 level. Planned start Jun 2023; status: withdrawn.
02
Drugs
bexmarilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05171062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171062.